Xeris Biopharma Holdings, Inc. XERS
9.10
0.15
1.68%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow XERS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
107.18% | (6.96%) | (108.59%) | 118.22% | |
| (4.52%) | 0.16% | 3.39% | (4.60%) | ||
ROIC |
4.82% | 12.65% | 18.32% | 18.88% | |
Return on Tangible Assets |
(13.87%) | 0.41% | 8.69% | (19.07%) | |
Average Days of Receivables |
73.72 | 63.85 | 65.26 | 63.23 | |
Free Cash Flow per Share |
0.06 | 0.17 | 0.28 | 0.32 | |
Free Cash Flow |
9.98 | 27.93 | 47.52 | 55.67 | |
Capital Expenditures |
(0.58) | (0.70) | (1.01) | (0.94) | |
Piotroski F-Score |
7.00 | 8.00 | 8.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
3.40% | 8.30% | 14.03% | 15.53% | |
Accounts Receivable Turnover |
5.61 | 6.38 | 6.14 | 6.04 | |
Accounts Payable Turnover |
5.88 | 15.87 | 4.99 | 4.79 | |
Inventory Turnover |
0.73 | 0.73 | 0.70 | 0.61 | |
Average Days of Payables |
57.96 | 26.37 | 94.24 | 75.68 | |
Days of Inventory on Hand |
599.12 | 588.82 | 610.05 | 656.01 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.04% | 10.68% | 10.23% | 10.38% | |
Selling, General and Administrative Expense of Revenue |
65.76% | 62.49% | 60.82% | 62.05% | |
Share Based Compensation of Revenue |
7.77% | 7.66% | 7.01% | 8.38% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.68) | 51.67 | 4.04 | (3.30) | |
Depreciation/Fixed assets |
3.23 | 3.25 | 3.21 | 3.37 | |
Capex/Depreciation |
(0.04) | (0.04) | (0.06) | (0.06) | |
Revenue per Share |
1.63 | 1.82 | 1.85 | 1.94 | |
Operating CF per Share |
0.06 | 0.18 | 0.28 | 0.33 | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(5.88%) | 0.19% | 3.81% | (5.12%) |
Columns are period end dates